We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 18, 2019

CV Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk

The Journal of Clinical Endocrinology and Metabolism


Additional Info

The Journal of Clinical Endocrinology and Metabolism
Cardiovascular Effects of Pioglitazone or Sulphonylureas According to Pretreatment Risk: Moving Towards Personalized Care
J. Clin. Endocrinol. Metab. 2019 May 06;[EPub Ahead of Print], O Vaccaro, G Lucisano, M Masulli, E Bonora, S Del Prato, AA Rivellese, CB Giorda, P Mocarelli, S Squatrito, AP Maggioni, G Riccardi, A Nicolucci

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading